Cookies

This site uses cookies and by using the site you are consenting to this. Find out what cookies are, why we use them and how to manage your settings in our cookie policy.

Changing your cookie settings

All browsers provide tools that allow you to control how they handle cookies: accept, reject or delete them. These settings are normally accessed via the 'preferences' or 'options' menu of the browser you are using. Read more...

C4X Discovery

A new dimension in drug discovery



Shareholder Information

Significant Shareholders

In so far as the company has been notified, the following table represents significant shareholders as at October 24th 2014;

Name Number of shares held Percentage of issued share capital
The Aquarius IV Fund LLP 4,864,375 15.07%
Andrew Almond 3,010,000 9.71%
Charles Blundell 3,035,000 9.79%
The Aquarius Origin Fund LLP 2,595,050 8.37%
Baillie Gifford & Co 2,213,467 7.14%
Andrew Black 2,500,000 8.07%
Aviva plc & its subsidiaries 3,098,855 10.00%

AIM securities in issue: 30,988,550 (no shares held in Treasury)

The percentage of AIM securities not in public hands is 63.94%

Directors and their interests

Name Number of shares held Percentage of issued share capital
Clive James Dix 591,250 1.91%
Piers Morgan 30,000 0.10%
Harry Finch 321,425 1.04%
Samuel Cameron Williams 1,119,625 3.61%
Alexander James Stevenson 485,403 1.57%

 
bioindustry-logo
 
onenucleus-logo
 
Copyright © 2014 C4X Discovery Holdings plc.
Registered in England and Wales with registered number 09134041.
Registered office: Unit 310 Ducie House, Ducie Street, Manchester, M1 2JW, United Kingdom.

Medilink Business Awards 2013 - Innovation